Induced pluripotent stem cell therapy (Sumitomo Dainippon/Keio University)

N/A

Report date: 2024/06/13 10:26:23

Base Information

Drug NameInduced pluripotent stem cell therapy (Sumitomo Dainippon/Keio University)
Drug Alias NameHLCR-011HLCR-012
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsMacular DegenerationRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHealios IncSumitomo Dainippon
China Registration ClassN/A

Develop Information

Active CompaniesHealios IncSumitomo DainipponSumitomo Chemical Co Ltd
Inactive CompaniesN/A
Active IndicationsMacular DegenerationRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A